Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.

Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ.

J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):213-9. doi: 10.1097/MPG.0b013e3182a98df2.

2.

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I.

Dig Dis Sci. 2015 Oct;60(10):3075-84. doi: 10.1007/s10620-015-3735-4.

PMID:
26044830
3.

Infliximab efficacy in pediatric ulcerative colitis.

Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M.

Inflamm Bowel Dis. 2005 Mar;11(3):213-8.

PMID:
15735427
4.

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R.

Gut. 2004 Jun;53(6):849-53.

5.

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.

Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A, Meucci G, Gasbarrini A, Guidi L, Lavagna A, Sostegni R, Onali S, Papi C, Kohn A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)..

J Crohns Colitis. 2014 Aug;8(8):852-8. doi: 10.1016/j.crohns.2014.01.006.

PMID:
24472490
6.

Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.

Yamamoto-Furusho JK, Uzcanga LF.

Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882.

PMID:
19005257
7.

Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.

Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, Bujanover Y, Shamir R.

J Crohns Colitis. 2013 Jun;7(5):369-76. doi: 10.1016/j.crohns.2012.03.006.

PMID:
22483567
8.

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.

Yamada S, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y, Tsuji Y, Nakase H.

BMC Gastroenterol. 2014 Apr 23;14:80. doi: 10.1186/1471-230X-14-80.

9.

Infliximab for hospitalized patients with severe ulcerative colitis.

Regueiro M, Curtis J, Plevy S.

J Clin Gastroenterol. 2006 Jul;40(6):476-81.

PMID:
16825928
10.
11.

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.

Rostholder E, Ahmed A, Cheifetz AS, Moss AC.

Aliment Pharmacol Ther. 2012 Mar;35(5):562-7. doi: 10.1111/j.1365-2036.2011.04986.x.

12.

Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease.

O'Donnell S, Stempak JM, Steinhart AH, Silverberg MS.

J Crohns Colitis. 2015 Oct;9(10):830-6. doi: 10.1093/ecco-jcc/jjv115.

PMID:
26116556
13.

Infliximab is effective in acute but not chronic childhood ulcerative colitis.

Russell GH, Katz AJ.

J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):166-70.

PMID:
15269622
14.

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.

Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, Gisbert JP.

Aliment Pharmacol Ther. 2012 Jan;35(2):275-83. doi: 10.1111/j.1365-2036.2011.04934.x.

15.

The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis.

Bressler B, Law JK, Al Nahdi Sheraisher N, Atkinson K, Byrne MF, Chung HV, Fishman M, Partovi N, Pearson D, Penner R, Enns RA.

Can J Gastroenterol. 2008 Nov;22(11):937-40.

16.

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Vahabnezhad E, Rabizadeh S, Dubinsky MC.

Inflamm Bowel Dis. 2014 Apr;20(4):606-13. doi: 10.1097/MIB.0000000000000003.

PMID:
24552827
17.

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

Jakobovits SL, Jewell DP, Travis SP.

Aliment Pharmacol Ther. 2007 May 1;25(9):1055-60.

18.

Use of infliximab in pediatric patients with inflammatory bowel disease.

Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):823-8.

PMID:
11485127
19.

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.

Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T.

J Gastroenterol Hepatol. 2010 May;25(5):886-91. doi: 10.1111/j.1440-1746.2009.06206.x.

PMID:
20546441
20.
Items per page

Supplemental Content

Support Center